This program discusses the role of endothelin-receptor antagonists and their unique function and role in the management of resistant hypertension, beyond their known role in the management of pulmonary arterial hypertension. More specifically, the education will focus on the worsened prognosis associated with diagnostic delay, the challenges with current treatment modalities, the lack of guidelines being updated to reflect current clinical practices, and providing the community with a more in-depth and better understanding of the profiles associated with endothelin-receptor antagonists.